Xuanyu Medical and Xiangrikui Medical Announce Strategic Partnership to Advance Pulsed Field Ablation Technology for Atrial Fibrillation Treatment
ShineyoMedical
Provider of Atrial Fibrillation Electrophysiology and Peripheral Vascular Intervention Solutions
Recently, ShineyoMedical and Xiang Rikui Medical Technology (Shanghai) Co., Ltd. (Xiang Rikui Medical) officially reached a strategic cooperation.Both parties announced that they will engage in in-depth cooperation around ShineyoMedical's independently developed Rhythpulse® Multi-Channel Cardiac Pulse Field Ablation System (PFA).Xiangrikui Healthcare will provide comprehensive support for this product, including brand operation, market promotion, and channel development, jointly promoting the clinical application and market coverage of this innovative technology in the field of atrial fibrillation treatment. ShineyoMedical, on the other hand, will focus on product manufacturing, clinical support, and subsequent technological iteration to ensure that the product performance remains in sync with international leading standards.
Background of Cooperation:
Technological Breakthroughs and Market Potential in Resonance
Pulsed Field Ablation (PFA), as a new generation technology for atrial fibrillation treatment, is gradually disrupting traditional radiofrequency and cryoablation techniques with its advantages of non-thermal ablation, strong tissue selectivity, short operation time, and low risk of complications. It has become a research and development hotspot in the global electrophysiology field. The Rhythpulse® system and its accompanying catheters, independently developed by ShineyoMedical, have been approved by the National Medical Products Administration (NMPA) and officially launched on February 26, 2025. The device features innovative real-time R-wave recognition, impedance monitoring, and autonomous electrode discharge selection, enabling precise ablation of the target area while avoiding damage to surrounding tissues, significantly improving the safety and efficiency of the procedure. The central helix-designed catheter, available in 10-30mm sizes, offers a more comfortable handling experience and better tissue contact.
Founder and CEO of ShineyoMedical
Mr. Shuguo Chen:
The current electrophysiology market in China is characterized by: accelerating domestic substitution but with foreign companies still dominating, market expansion driven by PFA innovative technologies, and a dual-driven approach of policy support and R&D advancement. In the current capital environment, emerging innovative medical device companies face increasing challenges in achieving full industry chain coverage—from R&D, production, commercialization to marketing—through continuous financing for core product pipelines and subsequent commercial development. Xiangrikui Healthcare excels in bridging the "last mile" from technical validation to commercial implementation with its "full-cycle service capabilities," while ShineyoMedical focuses on innovative R&D and manufacturing of medical devices, creating high synergy and complementarity between the two. ShineyoMedical is committed to delivering clinical innovation solutions that offer leading value and accessibility to doctors and patients, aligning seamlessly with Xiangrikui Healthcare’s founding mission of "Innovative healthcare, accessible to all." Both parties share a common foundation of cooperation principles. Through this collaboration, we look forward to promoting physician-engineering cooperation and academic exchanges in PFA technology, as well as bringing innovative and accessible medical devices to Chinese clinicians and patients more quickly.
Founder and CEO of Xiangrikui Healthcare
Ms. Shi Chunmin:
As a globally recognized revolutionary technology for arrhythmia treatment, pulsed field ablation (PFA) has entered a rapid development channel with its unique advantages. Based on profound insights into clinical needs in China, ShineyoMedical has developed a PFA solution that meets international standards while incorporating Chinese characteristics by deeply engaging with clinicians and listening to the opinions of Chinese experts. Rymo Medical is honored to partner strategically with ShineyoMedical, committing to value creation from technological innovation to clinical translation. Through complementary product portfolios, shared technical platforms, and coordinated clinical resources, both parties jointly provide physicians with value-added services covering the entire diagnosis and treatment process.
Enterprise Strength:
Innovation-Driven and Capital Support
ShineyoMedical is an innovative medical device company in China that leads in the dual-platform layout of electrophysiology and peripheral intervention. The company is committed to providing value-leading and inclusive innovative clinical solutions for doctors and patients in China. Relying on its self-developed technology platforms for active medical devices, vascular interventional catheters, and biomedical materials, ShineyoMedical has pioneered a series of innovative medical device products with independent intellectual property rights that fill domestic gaps in the fields of cardiac electrophysiology and peripheral vascular intervention. These include globally and domestically leading products such as the pulsed field ablation system (PFA) for treating paroxysmal atrial fibrillation and the venous closure system for treating varicose veins. Several innovative flagship products, including PFA, have been approved for marketing by NMPA. Since its establishment, the company has developed rapidly and received multiple rounds of investment from top venture capital institutions in the biopharmaceutical field. It has been honored with the titles of National High-tech Enterprise and Shanghai Specialized, Fine, Distinctive, and Innovative Small and Medium-sized Enterprise.
Since its establishment, Xiangrikui Medical Technology has always adhered to the mission of "innovative healthcare, accessible to all." By building a tripartite innovation ecosystem—creating a medical innovation transformation platform, a multidisciplinary talent training base, and an engine for high-quality medical resource distribution—the company has successfully established a professional, full-chain medical industry service platform. With a deep focus on core tracks in the pan-vascular field, including coronary intervention, cardiac electrophysiology, structural heart disease, cardiac surgery, and vascular surgery, it provides medical enterprises and clinical institutions with key business modules such as full-cycle brand strategy services, clinical technology transformation support, and the construction of evidence-based medical research systems. By integrating innovation elements from industry, academia, research, and medicine, the company continuously promotes the clinical transformation and widespread application of cutting-edge medical technologies, striving to become a strategic partner in the innovative development of the healthcare industry.
For PFA business cooperation with ShineyoMedical, please contact
15800832021
